Pfenex (PFNX) Announces Earnings Results

Pfenex (NYSEAMERICAN:PFNX) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10), Morningstar.com reports. The business had revenue of $3.57 million during the quarter, compared to the consensus estimate of $6.30 million.

Shares of NYSEAMERICAN PFNX traded up $0.20 during midday trading on Thursday, hitting $4.71. 2,401 shares of the company’s stock were exchanged, compared to its average volume of 155,190. Pfenex has a twelve month low of $2.07 and a twelve month high of $8.42.

PFNX has been the topic of several research analyst reports. Zacks Investment Research raised Pfenex from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Wednesday, October 10th. William Blair reissued an “outperform” rating on shares of Pfenex in a research report on Monday, September 10th.

In other Pfenex news, Director Phillip M. Schneider bought 11,000 shares of the business’s stock in a transaction dated Tuesday, September 11th. The shares were acquired at an average price of $4.99 per share, with a total value of $54,890.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Evert B. Schimmelpennink bought 10,000 shares of the business’s stock in a transaction dated Tuesday, September 11th. The shares were acquired at an average cost of $5.04 per share, for a total transaction of $50,400.00. The disclosure for this purchase can be found here. Insiders have bought a total of 26,000 shares of company stock worth $129,540 in the last three months.

Hedge funds and other institutional investors have recently modified their holdings of the company. Hilltop Holdings Inc. acquired a new position in Pfenex during the second quarter worth approximately $149,000. Algert Global LLC acquired a new position in Pfenex during the second quarter worth approximately $154,000. Alambic Investment Management L.P. acquired a new position in Pfenex during the second quarter worth approximately $563,000. Russell Investments Group Ltd. acquired a new position in Pfenex during the second quarter worth approximately $2,306,000. Finally, BlackRock Inc. increased its position in Pfenex by 257.1% during the second quarter. BlackRock Inc. now owns 1,316,873 shares of the biotechnology company’s stock worth $7,125,000 after buying an additional 948,102 shares during the period.

COPYRIGHT VIOLATION WARNING: “Pfenex (PFNX) Announces Earnings Results” was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.wkrb13.com/2018/11/08/pfenex-pfnx-announces-earnings-results.html.

About Pfenex

Pfenex Inc, a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study.

See Also: What are the Different Types of Leveraged Buyouts?

Earnings History for Pfenex (NYSEAMERICAN:PFNX)

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply